HPV vaccine MedImmune/GlaxoSmithKline.

摘要: MedImmune, in collaboration with GlaxoSmithKline, is developing a vaccine consisting of self-assembling, virus-like particles for the prevention human papillomavirus (HPV) infection genital tract and associated cervical cancer. The candidates include prototype vaccine, MEDI-501 (a directed against HPV-11), MEDI-503 (directed HPV-16) MEDI-504 HPV-18). Following phase I studies, HPV-16 HPV-18 components were combined into multivalent subsequent trials; this known as MEDI-517. Phase II trials MEDI-517 initiated by January 2000 are currently ongoing.